Drug Trial Radar · NCT00190268
Efficacy of 3,4-DAP in Fatigue Associated With Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Feb 21, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
126
Actual
Start
Feb 2005
Primary completion
Jun 2008
Study completion Jun 2008
Sponsor
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 19, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Rational of study : 3,4-diaminopyridine is suspected to improved the fatigue associated in patient's multiple sclerosis. In order to confirm this hypothesis, a randomized, controlled versus placebo, double blinded study is performed.
Conditions
- Multiple Sclerosis
Interventions
3,4-diaminopyridineDrug
3,4-diaminopyridine
Primary outcomes
What the sponsor says the trial is designed to measure.
- improvement of fatigue measured by a decrease of EMIF-SEP score compared to placebo group.Time frame: 43 months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Henri Mondor Hospital
Créteil, France
Pitié Salpetriere Hospital
Paris, France
Tenon Hospital
Paris, France
Pontchaillou Hospital
Rennes, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.